Android access offers more patients and families the ability to experience the groundbreaking EndeavorRx® treatment at scale

Akili Interactive (“Akili”), a leading prescription digital therapeutics company, today announced that EndeavorRx®, the first and only prescription video game treatment for kids 8-12 years old diagnosed with ADHD (see full indication below), is now available to patients on Google Play™ on devices supporting Android 9.0 or newer. With Android device users making up 46 percent of the mobile market¹, this expanded access offers new families and patients the opportunity to benefit from Akili’s first-of-its-kind treatment. The update comes just in time for the new school year, introducing Android device users to what's possible through the use of prescription digital therapeutics.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210916005288/en/

Child playing EndeavorRx, now available on Android devices (Photo: Business Wire)

“More than ever before, kids living with ADHD are facing increased stress and ever-changing routines that make it even harder for them to stay focused,” said Carl Gottlieb, SVP of Engineering at Akili Interactive. “It's incredibly important to us that every eligible child that can benefit from our product can access it. Our launch on Android devices is an important step toward that goal.”

This expansion is the latest in a series of notable milestones from Akili. In May 2021, Akili announced $160 million in Series D financing to support the commercial rollout of EndeavorRx and further research and development of new technologies to treat a broader range of cognitive conditions. Soon after, the company introduced enhancements to EndeavorRx gameplay, leveraging insights from gaming trends, caregiver and patient feedback, and real-world data to provide an interactive and engaging treatment experience for children with ADHD.

EndeavorRx offers a unique, personalized treatment through a video game experience. Created by a team of world-class neuroscientists and award-winning game designers, it uses sensory stimuli and simultaneous motor challenges designed to target areas of the brain that play a key role in attention function. Patients will find gameplay adapts in real-time, automatically adjusting difficulty levels based on their progress.

To learn more or download a guide on how to talk to a child’s doctor about EndeavorRx, please visit EndeavorRx.com.

EndeavorRx® Indication and Overview

EndeavorRx is the first-and-only FDA-cleared treatment delivered through a video game experience. EndeavorRx is indicated to improve attention function as measured by computer-based testing in children ages 8-12 years old with primarily inattentive or combined-type ADHD, who have a demonstrated attention issue. Patients who engage with EndeavorRx demonstrate improvements in a digitally assessed measure Test of Variables of Attention (TOVA®) of sustained and selective attention and may not display benefits in typical behavioral symptoms, such as hyperactivity. EndeavorRx should be considered for use as part of a therapeutic program that may include clinician-directed therapy, medication, and/or educational programs, which further address symptoms of the disorder. EndeavorRx is available by prescription only. It is not intended to be used as a stand-alone therapeutic and is not a substitution for a child’s medication. The most common side effect observed in children in EndeavorRx’s clinical trial was a feeling of frustration, as the game can be quite challenging at times. No serious adverse events were associated with its use. EndeavorRx is recommended to be used for approximately 25 minutes a day, 5 days a week, over initially at least 4 consecutive weeks, or as recommended by your child’s health care provider. To learn more about EndeavorRx, please visit www.EndeavorRx.com.

About Akili

Akili is combining scientific and clinical rigor with the ingenuity of the tech and entertainment industries to challenge the status quo of medicine. Akili is pioneering the development of digital treatments and care solutions to help people affected by cognitive impairments. Akili’s treatments are designed to directly activate the networks in the brain responsible for cognitive function and have been rigorously tested in extensive clinical studies, including prospective randomized, controlled trials. Driven by Akili’s belief that effective medicine can also be fun and engaging, Akili’s treatments are delivered through captivating action video game experiences. For more information, please visit www.akiliinteractive.com.

¹Share of mobile operating systems in North America 2018-2021, Statista

View source version on businesswire.com: https://www.businesswire.com/news/home/20210916005288/en/